Search Result

Results for "

NVP

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (1) Apoptosis (22) Autophagy (12) Bcr-Abl (1) c-Kit (1) c-Met/HGFR (1) CDK (2) Dipeptidyl Peptidase (6) Drug Metabolite (1) E1/E2/E3 Enzyme (3) EGFR (1) Ephrin Receptor (2) FAK (1) Ferroptosis (4) FGFR (3) FLT3 (1) HDAC (5) HIV (6) HSP (3) IGF-1R (4) iGluR (2) Insulin Receptor (4) Isotope-Labeled Compounds (6) JAK (3) MDM-2/p53 (3) mTOR (5) Parasite (3) PARP (1) PDGFR (1) PERK (2) PI3K (10) PI4K (1) Prostaglandin Receptor (1) Pyk2 (1) Ras (2) RET (2) Reverse Transcriptase (2) Smo (3) Tie (1) VEGFR (3)
By Research Areas:	Cancer (52) Cardiovascular Disease (1) Endocrinology (4) Infection (5) Metabolic Disease (8) Neurological Disease (2)

By Targets:

Anaplastic lymphoma kinase (ALK) (1)

Apoptosis (22)

Autophagy (12)

Bcr-Abl (1)

c-Kit (1)

c-Met/HGFR (1)

CDK (2)

Dipeptidyl Peptidase (6)

Drug Metabolite (1)

E1/E2/E3 Enzyme (3)

EGFR (1)

Ephrin Receptor (2)

FAK (1)

Ferroptosis (4)

FGFR (3)

FLT3 (1)

HDAC (5)

HIV (6)

HSP (3)

IGF-1R (4)

iGluR (2)

Insulin Receptor (4)

Isotope-Labeled Compounds (6)

JAK (3)

MDM-2/p53 (3)

mTOR (5)

Parasite (3)

PARP (1)

PDGFR (1)

PERK (2)

PI3K (10)

PI4K (1)

Prostaglandin Receptor (1)

Pyk2 (1)

Ras (2)

RET (2)

Reverse Transcriptase (2)

Smo (3)

Tie (1)

VEGFR (3)

By Research Areas:

Cancer (52)

Cardiovascular Disease (1)

Endocrinology (4)

Infection (5)

Metabolic Disease (8)

Neurological Disease (2)

Inhibitors & Agonists

Inhibitory Antibodies

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10570

Nevirapine 4 Publications Verification BI-RG 587; NSC 641530; NVP	HIV Reverse Transcriptase Parasite	Infection Cancer
Nevirapine is a non-nucleoside inhibitor of HIV-1 reverse transcriptase used to treat and prevent HIV/AIDS; with a K_i of 270 μM .

HY-12214A

NVP-2 20+ Cited Publications	CDK Apoptosis	Cancer
NVP-2 is a potent and selective ATP-competitive cyclin dependent kinase 9 (CDK9) probe, inhibits CDK9/CycT activity with an IC₅₀ of 0.514 nM. NVP-2 displays inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases with IC₅₀ values of 0.584 µM, 0.706 µM, and 0.605 µM, respectively. NVP-2 induces cell apoptosis.

HY-15954A

NVP-CGM097 (stereoisomer) CGM097 stereoisomer; (R)-NVP-Cgm097	Others	Others
NVP-CGM097 (stereoisomer) is a stereoisomer of NVP-CGM097, with no special bioactivity. NVP-CGM097 is a potent and selective MDM2 inhibitor.

HY-13945

NVP 231 2 Publications Verification	Apoptosis	Cancer
NVP 231 is a potent, specific, and reversible ceramide kinase (CerK) inhibitor(IC₅₀=12 nM) that competitively inhibits binding of ceramide to CerK . NVP 231 induces cell apoptosis by increasing DNA fragmentation and caspase-3 and caspase-9 cleavage .

HY-15456

NVP-BVU972	c-Met/HGFR	Cancer
NVP-BVU972 is an selective and potent Met inhibitor, with an IC₅₀ of 14 nM. NVP-BVU972 also exhibits good anti-proliferative activity against Met with drug-resistant mutations and inhibits phosphorylation. NVP-BVU972 can be used in study of cancer .

HY-146260

NVP-CLR457	PI3K	Cancer
NVP-CLR457 (compound 40) is an orally active, potent and balanced pan-class I PI3K inhibitor. NVP-CLR457 shows a clear dose-dependent PK/PD/efficacy relationship. NVP-CLR457 has antitumor activity .

HY-14292

NVP-DPP728	Dipeptidyl Peptidase	Metabolic Disease
NVP-DPP728 is a potent, reversible and nitrile-dependent dipeptidyl peptidase IV (DPP-IV) inhibitor. NVP-DPP728 can inhibit human DPP-IV amidolytic activity with a K_i of 11 nM. NVP-DPP728 inhibits degradation of glucagon-like peptide-1 (GLP-1) and thereby potentiates insulin release in response to glucose intake. NVP-DPP728 can be used for researching diabetes .

HY-132530S

NVP-BEZ 235-d3

Isotope-Labeled Compounds Others

NVP-BEZ 235-d3 is the deuterium labeled NVP-BEZ 235 .
HY-13258

NVP-BHG712 isomer

1 Publications Verification

Ephrin Receptor Cancer

NVP-BHG712 isomer, a regioisomer of NVP-BHG712, shows conserved non-bonded binding to EPHA2 and EPHB4 .

NVP-BEZ 235-d3	Isotope-Labeled Compounds	Others
NVP-BEZ 235-d3 is the deuterium labeled NVP-BEZ 235 .

NVP-BHG712 isomer 1 Publications Verification	Ephrin Receptor	Cancer
NVP-BHG712 isomer, a regioisomer of NVP-BHG712, shows conserved non-bonded binding to EPHA2 and EPHB4 .

HY-14293

NVP-DPP728 dihydrochloride	Dipeptidyl Peptidase	Metabolic Disease
NVP-DPP728 dihydrochloride is a potent, selective and orally active dipeptidyl peptidase IV (DPP-IV) inhibitor with a K_i of 11 nM. NVP-DPP728 dihydrochloride can be used for the research of diabetes mellitus .

HY-144998

NVP-DKY709

Others Cancer

NVP-DKY709 is a potent IKZF2 inhibitor for the research of cancers.

NVP-DKY709	Others	Cancer
NVP-DKY709 is a potent IKZF2 inhibitor for the research of cancers.

HY-50866

NVP-AEW541 5+ Cited Publications AEW541	IGF-1R Insulin Receptor Autophagy	Endocrinology Cancer
NVP-AEW541 (AEW541 ) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC₅₀ value of 0.15 μM. NVP-AEW541 also inhibits InsR, IC₅₀ with a value of 0.14 μM. NVP-AEW541 has antitumor activity .

HY-50866B

NVP-AEW541 dihydrochloride AEW541 dihydrochloride	IGF-1R Insulin Receptor Autophagy	Cancer
NVP-AEW541 dihydrochloride (AEW541 dihydrochloride) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC₅₀ value of 0.15 μM. NVP-AEW541 dihydrochloride also inhibits InsR, IC₅₀ with a value of 0.14 μM. NVP-AEW541 dihydrochloride has antitumor activity .

HY-13203

NVP-TAE 226 5+ Cited Publications TAE226	FAK Pyk2 IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
NVP-TAE 226 (TAE226) is a potent and ATP-competitive dual FAK and IGF-1R inhibitor with IC₅₀s of 5.5 nM and 140 nM, respectively. NVP-TAE 226 (TAE226) also effectively inhibits Pyk2 and insulin receptor (InsR) with IC₅₀s of 3.5 nM and 44 nM, respectively .

HY-150061

NVP-BBD130	PI3K mTOR	Cancer
NVP-BBD130 is a potent, stable, ATP-competitive and orally active dual PI3K and mTOR inhibitor . NVP-BBD130 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-100394

NVP-BAW2881

BAW2881
Tie VEGFR Endocrinology Cancer

NVP-BAW2881 (BAW2881) is a potent and selective VEGFR2 inhibitor with an IC₅₀ of 4 nM.
HY-16355

NVP-QAV-572

PI3K Cancer

NVP-QAV-572 is a PI3K inhibitor extracted from patent US7998990B2, Compound Example 8, has an IC₅₀ of 10 nM.

NVP-BAW2881 BAW2881	Tie VEGFR	Endocrinology Cancer
NVP-BAW2881 (BAW2881) is a potent and selective VEGFR2 inhibitor with an IC₅₀ of 4 nM.

NVP-QAV-572	PI3K	Cancer
NVP-QAV-572 is a PI3K inhibitor extracted from patent US7998990B2, Compound Example 8, has an IC₅₀ of 10 nM.

HY-10252

NVP-ADW742 2 Publications Verification ADW742; GSK 552602A; ADW	IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
NVP-ADW742 (ADW742) is an orally active, selective IGF-1R tyrosine kinase inhibitor with an IC₅₀ of 0.17 μM. NVP-ADW742 inhibits insulin receptor (InsR) with an IC₅₀ of 2.8 μM. NVP-ADW742 induces pleiotropic antiproliferative/proapoptotic biologic sequelae in tumor cells .

HY-15954

NVP-CGM097

1 Publications Verification

CGM097
MDM-2/p53 E1/E2/E3 Enzyme Cancer

NVP-CGM097 is a potent and selective MDM2 inhibitor with IC₅₀ of 1.7±0.1 nM for hMDM2.

NVP-CGM097 1 Publications Verification CGM097	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
NVP-CGM097 is a potent and selective MDM2 inhibitor with IC₅₀ of 1.7±0.1 nM for hMDM2.

HY-10192

NVP-TAE 684 10+ Cited Publications TAE 684	Anaplastic lymphoma kinase (ALK) Apoptosis	Cancer
NVP-TAE 684 (TAE 684) is a highly potent and selective ALK inhibitor, which blocks the growth of ALCL-derived and ALK-dependent cell lines with IC₅₀ values between 2 and 10 nM .

HY-13990

NVP-TNKS656 TNKS656	PARP Apoptosis	Cancer
NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor with IC₅₀ of 6 nM, and is > 300 fold selectivity against PARP1 and PARP2.

HY-18658

Siremadlin 4 Publications Verification NVP-HDM201; HDM201	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Siremadlin (NVP-HDM201) is a potent, orally bioavailable and highly specific p53-MDM2 interaction inhibitor.

HY-15954B

NVP-CGM097 sulfate 1 Publications Verification CGM097 sulfate	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
NVP-CGM097 sulfate is a potent and selective MDM2 inhibitor with IC₅₀ of 1.7±0.1 nM for hMDM2.

HY-13258A

NVP-BHG712 4 Publications Verification BHG712	Ephrin Receptor	Cancer
NVP-BHG712 is an oral active EphB4 kinase autophosphorylation inhibitor, with IC₅₀ values of 3.3 nM and 3.0 nM for EphA2 and EphB4, respectively .

HY-15190

NVP-HSP990 2 Publications Verification HSP-990	HSP Apoptosis	Cancer
NVP-HSP990 is a potent, selective and orally active Hsp90 inhibitor, with IC₅₀ values of 0.6, 0.8, and 8.5 nM for Hsp90α, Hsp90β, and Grp94, respectively.

HY-12294

PEAQX NVP-AAM077	iGluR	Neurological Disease
PEAQX(NVP-AAM 077) is a potent and orally active NMDA antagonist with a 15-fold preference for human NMDA receptors with the 1A/2A(IC50=270 nM), rather than 1A/2B(29,600 nM).

HY-14722A

NVP-BSK805 dihydrochloride 1 Publications Verification	JAK	Cancer
NVP-BSK805 dihydrochloride is an ATP-competitive JAK2 inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .

HY-14722C

NVP-BSK805 trihydrochloride	JAK	Cancer
NVP-BSK805 trihydrochloride trihydrochloride is an ATP-competitive JAK2 inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .

HY-14722

NVP-BSK805 1 Publications Verification	JAK	Cancer
NVP-BSK805 is an ATP-competitive JAK2 inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .

HY-15241

NVP-LCQ195

LCQ-195; AT9311
CDK Cancer

NVP-LCQ195 (AT9311; LCQ195) is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.

NVP-LCQ195 LCQ-195; AT9311	CDK	Cancer
NVP-LCQ195 (AT9311; LCQ195) is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.

HY-13311A

Infigratinib phosphate 20+ Cited Publications BGJ-398 phosphate; NVP-BGJ398 phosphate	FGFR	Cancer
Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the FGFR family with IC₅₀ of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

HY-12294A

PEAQX tetrasodium hydrate 5 Publications Verification NVP-AAM077 tetrasodium hydrate	iGluR Apoptosis	Neurological Disease
PEAQX (NVP-AAM077) tetrasodium hydrate is a potent, selective and orally active NMDA antagonist, with IC₅₀ values of 270 nM and 29600 nM for hNMDAR 1A/2A and hNMDAR 1A/2B, respectively .

HY-13311

Infigratinib 20+ Cited Publications BGJ-398; NVP-BGJ398	FGFR Apoptosis	Cancer
Infigratinib (BGJ-398; NVP-BGJ398) is a potent inhibitor of the FGFR family with IC₅₀s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

HY-139612

Opnurasib 1 Publications Verification JDQ-443; NVP-JDQ443	Ras PERK	Cancer
Opnurasib (JDQ-443) (NVP-JDQ443) is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). Opnurasib shows antitumor activity .

HY-16768

Fevipiprant 1 Publications Verification QAW039; NVP-QAW039	Prostaglandin Receptor	Cardiovascular Disease
Fevipiprant (QAW039, NVP-QAW039) is s an orally active, selective, reversible prostaglandin D2 (DP2) receptor antagonist with an K_d value of 1.14 nM. Fevipiprant has the potential for the research of bronchial asthma .

HY-10942

VER-82576 5 Publications Verification NVP-BEP800	HSP	Cancer
VER-82576 (NVP-BEP800) is a potent, orally available and selective Hsp90 inhibitor, with an IC₅₀ of 58 nM for Hsp90β; VER-82576 also slightly blocks Grp94 and Trap-1, with IC₅₀s of 4.1 and 5.5 μM, respectively.

HY-70063

Buparlisib Maximum Cited Publications 59 Publications Verification BKM120; NVP-BKM120	PI3K Apoptosis	Cancer
Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with IC₅₀s of 52, 166, 116 and 262 nM for p110α, p110β, p110δ and p110γ, respectively.

HY-18658A

Siremadlin (R Enantiomer) NVP-HDM201 (R Enantiomer); HDM201 (R Enantiomer)	Others	Others
Siremadlin R Enantiomer (NVP-HDM201 R Enantiomer) is the R enantiomer of Siremadlin. Siremadlin is a potent and highly specific MDM-2/p53 inhibitor.

HY-19624

NVP-ACC789 ACC-789; ZK202650	VEGFR PDGFR	Cancer
NVP-ACC789 is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR-β with IC₅₀s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively.

HY-13334

BGT226 maleate 5 Publications Verification NVP-BGT226 maleate	PI3K mTOR Autophagy Apoptosis	Cancer
BGT226 (NVP-BGT226 maleate) is a PI3K (with IC₅₀s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ) /mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells .

HY-13334A

BGT226 5 Publications Verification NVP-BGT226	PI3K mTOR Autophagy	Cancer
BGT226 (NVP-BGT226) is a PI3K (with IC₅₀s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ)/mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells .

HY-13333

NVP-BAG956

BAG 956
PI3K Cancer

NVP-BAG956 is an ATP-competitive PI3K inhibitor with IC50s of 34, 56, 112 and 444 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively.

NVP-BAG956 BAG 956	PI3K	Cancer
NVP-BAG956 is an ATP-competitive PI3K inhibitor with IC50s of 34, 56, 112 and 444 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively.

HY-10224

Panobinostat 50+ Cited Publications LBH589; NVP-LBH589	HDAC Autophagy HIV Apoptosis	Cancer
Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities . Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells . Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma .

HY-10224S

Panobinostat-d4 LBH589-d₄; NVP-LBH589-d₄	HDAC Autophagy HIV Apoptosis	Cancer
Panobinostat-d₄ is the deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

HY-10224S1

Panobinostat-d4 hydrochloride LBH589-d₄ hydrochloride; NVP-LBH589-d₄ hydrochloride	Isotope-Labeled Compounds HDAC Autophagy HIV Apoptosis	Cancer
Panobinostat-d₄ (hydrochloride) is deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

HY-10045

AEE788

3 Publications Verification

NVP-AEE 788
EGFR Apoptosis Cancer

AEE788 is an inhibitor of the EGFR and ErbB2 with IC₅₀ values of 2 and 6 nM, respectively.

AEE788 3 Publications Verification NVP-AEE 788	EGFR Apoptosis	Cancer
AEE788 is an inhibitor of the EGFR and ErbB2 with IC₅₀ values of 2 and 6 nM, respectively.

HY-15174

Dactolisib Tosylate 45+ Cited Publications BEZ235 Tosylate; NVP-BEZ 235 Tosylate	PI3K mTOR Autophagy	Cancer
Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and mTOR kinase inhibitor with IC₅₀ values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.

HY-14291

Vildagliptin 4 Publications Verification LAF237; NVP-LAF 237	Dipeptidyl Peptidase Ferroptosis Apoptosis	Metabolic Disease
Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity .

HY-15002

AST 487 4 Publications Verification NVP-AST 487	RET FLT3 VEGFR c-Kit Bcr-Abl	Cancer
AST 487 is a RET kinase inhibitor with IC₅₀ of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits Flt-3 with IC₅₀ of 520 nM.

HY-14291S2

Vildagliptin-13C5,15N LAF237-¹³C₅,¹⁵N; NVP-LAF 237-¹³C₅,¹⁵N	Isotope-Labeled Compounds	Metabolic Disease
Vildagliptin- ¹³C₅, ¹⁵N (LAF237- ¹³C₅, ¹⁵N; NVP-LAF 237- ¹³C₅, ¹⁵N) is a ¹³C- and ¹⁵N-labeled Vildagliptin (HY-14291). Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity .

Cat. No.	Product Name	Chemical Structure

HY-14291S

Vildagliptin-d3
Vildagliptin-d₃ is the deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1][2].

HY-132530S

NVP-BEZ 235-d3

NVP-BEZ 235-d3 is the deuterium labeled NVP-BEZ 235 .

HY-10224S

Panobinostat-d4

Panobinostat-d₄ is the deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

HY-10224S1

Panobinostat-d4 hydrochloride

Panobinostat-d₄ (hydrochloride) is deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

HY-14291S2

Vildagliptin-13C5,15N
Vildagliptin- ¹³C₅, ¹⁵N (LAF237- ¹³C₅, ¹⁵N; NVP-LAF 237- ¹³C₅, ¹⁵N) is a ¹³C- and ¹⁵N-labeled Vildagliptin (HY-14291). Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity .

HY-14291S1

Vildagliptin-d7
Vildagliptin-d₇ is deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1].

HY-13311S

Infigratinib-d3
Infigratinib-d3 is a deuterated analog of infigratinib. Infigratinib is an effective inhibitor of the FGFR family, with IC₅₀ values of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively .

HY-16582AS

Sonidegib-d4
Sonidegib-d4 is a isotope of Sonidegib. Sonidegib is a potent and selective Smo antagonist with IC₅₀ of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: